P54289 (CA2D1_HUMAN) Homo sapiens (Human)
Voltage-dependent calcium channel subunit alpha-2/delta-1 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
26 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| P/Q type calcium channel in complex with omega-conotoxin MVIIC |
Heteromer O00555; P37300; P54284; | 1×NAG; 3×NAG; 1×NAG; 2×NAG; 3×CA; 5×CLR; 1×PT5; 3×Y01; 2×3PE; | ||||
| Assess | ||||||
| P/Q type calcium channel |
Heteromer O00555; P54284; | 1×NAG; 3×NAG; 1×NAG; 1×PS1; 5×CLR; 1×PT5; 2×CA; 2×NAG; 3×Y01; 2×3PE; | ||||
| Assess | ||||||
| P/Q type calcium channel in complex with omega-Agatoxin IVA |
Heteromer O00555; P54284; | 1×NAG; 3×NAG; 1×NAG; 3×CA; 2×NAG; 5×CLR; 1×PT5; 3×Y01; 1×3PE; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.2 (Class I) in the presence of pinaverium at 3.0 An… |
Heteromer P54284; Q13936; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 1×3PE; 3×CLR; 3×NAG; 1×PT5; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.2 in the presence of amiodarone and sofosbuvir at 3… |
Heteromer P54284; Q13936; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 1×BBI; 1×WG6; 2×3PE; 4×CLR; 2×NAG; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.2 (Class II) in the presence of pinaverium at 3.2 A… |
Heteromer Q13936; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 1×9Z9; 1×WB9; 2×NAG; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.2 at 2.9 Angstrom resolution |
Heteromer P54284; Q13936; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 1×3PE; 4×CLR; 3×NAG; 1×PT5; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.3 treated with 1.4 mM Sofosbuvir at 3.3 Angstrom re… |
Heteromer P54284; Q01668; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 2×NAG; | ||||
| Assess | ||||||
| Human R-type voltage-gated calcium channel Cav2.3 at 3.1 Angstrom resolution |
Heteromer P54284; Q15878; | 4×NAG; 1×NAG; 2×CA; 5×CLR; 2×3PE; 1×PT5; 3×NAG; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.3 in the presence of Amiodarone and Sofosbuvir at 3… |
Heteromer P54284; Q01668; | 1×NAG; 3×NAG; 1×NAG; 1×BBI; 1×WG6; 2×CA; 1×NAG; | ||||
| Assess | ||||||
| Human R-type voltage-gated calcium channel Cav2.3 CH2II-deleted mutant at 3.1 Angstrom resolution |
Heteromer Q15878; | 4×NAG; 1×NAG; 2×CA; 3×NAG; | ||||
| Assess | ||||||
| Human N-type voltage-gated calcium channel Cav2.2 at 3.1 Angstrom resolution |
Heteromer P54284; Q00975; | 1×NAG; 3×NAG; 1×NAG; 3×NAG; 2×CA; 3×Y01; 4×CLR; 2×3PE; 1×PT5; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.3 in the presence of Amiodarone at 3.1 Angstrom res… |
Heteromer P54284; Q01668; | 1×NAG; 3×NAG; 1×NAG; 1×BBI; 2×CA; 1×3PE; 2×NAG; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.3 in the presence of cinnarizine at 3.1 Angstrom re… |
Heteromer P54284; Q01668; | 1×NAG; 3×NAG; 1×NAG; 1×N90; 3×NAG; 2×CA; 1×Y01; 1×3PE; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.2 in the presence of calciseptine at 3.2 Angstrom r… |
Heteromer P22947; P54284; Q13936; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 2×CLR; 3×NAG; | ||||
| Assess | ||||||
| Human N-type voltage-gated calcium channel Cav2.2 in the presence of ziconotide at 3.0 Angstrom res… |
Heteromer P05484; P54284; Q00975; | 1×NAG; 3×NAG; 1×NAG; 3×NAG; 2×CA; 2×Y01; 5×CLR; 2×3PE; 1×PT5; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.2 in the presence of calciseptine, amlodipine and p… |
Heteromer P22947; P54284; Q13936; | 1×NAG; 3×NAG; 1×NAG; 2×CA; 5×CLR; 3×NAG; 1×PT5; 1×3PE; 1×6UB; | ||||
| Assess | ||||||
| Human L-type voltage-gated calcium channel Cav1.3 at 3.0 Angstrom resolution |
Heteromer P54284; Q01668; | 4×NAG; 1×NAG; 1×NAG; 2×CA; 3×CLR; 1×3PE; 2×NAG; | ||||
| Assess | ||||||
| Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, apo state |
Heteromer Q00975; Q02641; | 3×NAG; 18×R16; 3×Y01; 1×PT5; 2×CA; 8×NAG; | ||||
| Assess | ||||||
| Structure of human R-type voltage-gated CaV2.3-alpha2/delta1-beta1 channel complex in the ligand-fr… |
Heteromer Q02641; Q15878; | 3×NAG; 6×Y01; 7×R16; 1×3PE; 2×CA; 8×NAG; | ||||
| Assess | ||||||
| Structure of human R-type voltage-gated CaV2.3-alpha2/delta1-beta1 channel complex in the topiramat… |
Heteromer Q02641; Q15878; | 3×NAG; 9×Y01; 6×R16; 2×3PE; 2×CA; 1×TOR; 8×NAG; | ||||
| Assess | ||||||
| Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, bound to ziconotide |
Heteromer P05484; Q00975; Q02641; | 3×NAG; 18×R16; 3×Y01; 1×PT5; 2×CA; 8×NAG; | ||||
| Assess | ||||||
| Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, bound to CaV2.2-bloc… |
Heteromer Q00975; Q02641; | 3×NAG; 15×R16; 3×Y01; 1×PT5; 1×6I7; 2×CA; 8×NAG; | ||||
| Assess | ||||||
| Human N-type voltage gated calcium channel CaV2.2-alpha2/delta1-beta1 complex, bound to PD173212 |
Heteromer Q00975; Q02641; | 3×NAG; 16×R16; 3×Y01; 1×PT5; 1×6IX; 2×CA; 8×NAG; | ||||
| Assess | ||||||
| Structure of human alpha-2/delta-1 with mirogabalin | monomer | 2×NAG; 7×NAG; 1×8X9; | ||||
| Assess | ||||||
| Structure of human alpha-2/delta-1 without mirogabalin | monomer | 1×NAG; 4×NAG; | ||||
| Assess | ||||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7mix.1.C | monomer | 0.81 | 100.00 | |||
| Assess | ||||||
| 3jbr.1.D | monomer | 0.50 | 3×NAG; | 69.81 | ||
| Assess | ||||||
7 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 7mix.1.C | monomer | 0.81 | 99.91 | ||
| Assess | ||||||
| Isoform 3 | 7mix.1.C | monomer | 0.81 | 1×NAG; 1×NAG; 1×NAG; 1×NAG; | 99.91 | |
| Assess | ||||||
| Isoform 3 | 3jbr.1.D | monomer | 0.50 | 3×NAG; | 68.95 | |
| Assess | ||||||
| Isoform 4 | 7mix.1.C | monomer | 0.81 | 1×NAG; 1×NAG; 1×NAG; 1×NAG; | 100.00 | |
| Assess | ||||||
| Isoform 4 | 3jbr.1.D | monomer | 0.50 | 3×NAG; | 69.14 | |
| Assess | ||||||
| Isoform 5 | 7mix.1.C | monomer | 0.82 | 100.00 | ||
| Assess | ||||||
| Isoform 5 | 3jbr.1.D | monomer | 0.50 | 3×NAG; | 69.10 | |
| Assess | ||||||